{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:38:50Z","timestamp":1792186730097,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,16]],"date-time":"2012-06-16T00:00:00Z","timestamp":1339804800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00520-012-1500-1","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T14:33:14Z","timestamp":1340029994000},"page":"129-137","source":"Crossref","is-referenced-by-count":128,"title":["Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study"],"prefix":"10.1007","volume":"21","author":[{"given":"Jos\u00e9 M.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,16]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00520-009-0772-6","volume":"18","author":"W Lasheen","year":"2010","unstructured":"Lasheen W, Walsh D (2010) The cancer anorexia\u2013cachexia syndrome: myth or reality? Support Care Cancer 18:265\u2013272","journal-title":"Support Care Cancer"},{"key":"1500_CR2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89:381\u2013410","journal-title":"Physiol Rev"},{"key":"1500_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mhj.2002.124052","volume":"144","author":"S Adamopoulos","year":"2002","unstructured":"Adamopoulos S, Parissis JT, Georgiadis M et al (2002) Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas\/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 144:359\u2013364","journal-title":"Am Heart J"},{"key":"1500_CR4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2407-10-50","volume":"10","author":"O Arrieta","year":"2010","unstructured":"Arrieta O, Michel Ortega RM, Villanueva-Rodr\u00edguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel\u2013cisplatin chemotherapy: a prospective study. BMC Cancer 10:50. doi: 10.1186\/1471-2407-10-50","journal-title":"BMC Cancer"},{"key":"1500_CR5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","volume":"69","author":"WD Dewys","year":"1980","unstructured":"Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491\u2013497","journal-title":"Am J Med"},{"key":"1500_CR6","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","volume":"28","author":"AJ Davidoff","year":"2010","unstructured":"Davidoff AJ, Tang M, Seal B, Edelman MJ (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28:2191\u20132197. doi: 10.1200\/JCO.2009.25.4052","journal-title":"J Clin Oncol"},{"key":"1500_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00520-009-0722-3","volume":"18","author":"G Mantovani","year":"2010","unstructured":"Mantovani G, Madeddu C (2010) Cancer cachexia: medical management. Support Care Cancer 18:1\u20139. doi: 10.1007\/s00520-009-0722-3","journal-title":"Support Care Cancer"},{"key":"1500_CR8","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","volume":"89","author":"NM Neary","year":"2004","unstructured":"Neary NM, Small CJ, Wren AM et al (2004) Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2832\u20132836. doi: 10.1210\/jc.2003-031768","journal-title":"J Clin Endocrinol Metab"},{"key":"1500_CR9","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1002\/cncr.21013","volume":"103","author":"M Fouladiun","year":"2005","unstructured":"Fouladiun M, K\u00f6rner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care: correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103:2189\u20132198. doi: 10.1002\/cncr.21013","journal-title":"Cancer"},{"key":"1500_CR10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","volume":"83","author":"JE Morley","year":"2006","unstructured":"Morley JE, Thomas DR, Wilson M-MG (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735\u2013743","journal-title":"Am J Clin Nutr"},{"key":"1500_CR11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1365-2265.2002.01540.x","volume":"56","author":"AL Crown","year":"2002","unstructured":"Crown AL, Cottle K, Lightman SL et al (2002) What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf) 56:723\u2013733. doi: 10.1046\/j.1365-2265.2002.01540.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1500_CR12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjc.6604148","volume":"98","author":"F Strasser","year":"2008","unstructured":"Strasser F, Lutz TA, Maeder MT et al (2008) Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia\/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 98:300\u2013308. doi: 10.1038\/sj.bjc.6604148","journal-title":"Br J Cancer"},{"key":"1500_CR13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","volume":"402","author":"M Kojima","year":"1999","unstructured":"Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656\u2013660","journal-title":"Nature"},{"key":"1500_CR14","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1210\/jc.86.12.5992","volume":"86","author":"AM Wren","year":"2001","unstructured":"Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992. doi: 10.1210\/jc.86.12.5992","journal-title":"J Clin Endocrinol Metab"},{"key":"1500_CR15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.12-5-594","volume":"12","author":"JM Garcia","year":"2007","unstructured":"Garcia JM, Polvino WJ (2007) Effect on body and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12:594\u2013600","journal-title":"Oncologist"},{"key":"1500_CR16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ghir.2008.12.003","volume":"19","author":"JM Garcia","year":"2009","unstructured":"Garcia JM, Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19:267\u2013273. doi: 10.1016\/j.ghir.2008.12.003","journal-title":"Growth Horm IGF Res"},{"key":"1500_CR17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-149-9-200811040-00003","volume":"149","author":"R Nass","year":"2008","unstructured":"Nass R, Pezzoli SS, Oliveri MC et al (2008) Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149:601\u2013611","journal-title":"Ann Intern Med"},{"key":"1500_CR18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/eje.0.1500447","volume":"150","author":"T Akamizu","year":"2004","unstructured":"Akamizu T, Takaya K, Irako T et al (2004) Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocr 150:447\u2013455. doi: 10.1530\/eje.0.1500447","journal-title":"Eur J Endocr"},{"key":"1500_CR19","unstructured":"World Medical Association: The World Medical Association: policy: World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Amendments through 55th WMA General Assembly, Tokyo; 2004. Available at: 40news\/20archives\/2004\/2004_24\/index.html. Accessed February 8, 2011"},{"key":"1500_CR20","unstructured":"United States Food and Drug Administration, Department of Health and Human Services: FDA Good Clinical Practice Program. Available at http:\/\/www.fda.gov\/ScienceResearch\/SpecialTopics\/RunningClinicalTrials\/ucm155713.htm . Accessed February 8, 2011"},{"key":"1500_CR21","unstructured":"European Union Directive 91\/507\/EEC: Commission Directive 91\/507\/EEC of 19 July 1991: modifying the Annex to Council Directive 75\/318\/EEC on the approximation of the laws of member states relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products. Available at http:\/\/eur-lex.europa.eu\/smartapi\/cgi\/sga_doc?smartapi!celexplus!prod!DocNumber&lg=en&type_doc=Directive&an_doc=1991&nu_doc=507 . Accessed February 8, 2011"},{"key":"1500_CR22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"1500_CR23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","volume":"4","author":"PJ Hesketh","year":"1999","unstructured":"Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191\u2013196","journal-title":"Oncologist"},{"key":"1500_CR24","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5","volume":"88","author":"VT Chang","year":"2000","unstructured":"Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. Cancer 88:2164\u20132171","journal-title":"Cancer"},{"key":"1500_CR25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jpainsymman.2004.11.007","volume":"29","author":"JL Palmer","year":"2005","unstructured":"Palmer JL, Fisch MJ (2005) Association between symptom distress and survival in outpatients seen in a palliative care cancer center. J Pain Symptom Manag 29:565\u2013571. doi: 10.1016\/j.jpainsymman.2004.11.007","journal-title":"J Pain Symptom Manag"},{"key":"1500_CR26","first-page":"283","volume":"6","author":"DW Robinson Jr","year":"2008","unstructured":"Robinson DW Jr, Eisenberg DF, Cella D et al (2008) The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol 6:283\u2013290","journal-title":"J Support Oncol"},{"key":"1500_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF02260861","volume":"4","author":"DF Cella","year":"1995","unstructured":"Cella DF, VonRoenn J, Lloyd S, Browder HP (1995) The Bristol-Myers Anorexia\/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia\/cachexia. Qual Life Res 4:221\u2013231","journal-title":"Qual Life Res"},{"key":"1500_CR28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MCO.0b013e32832a7902","volume":"12","author":"DC McMillan","year":"2009","unstructured":"McMillan DC (2009) Systemic inflammation, nutritional status, and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223\u2013226","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1500_CR29","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1210\/jc.2004-1788","volume":"90","author":"JM Garcia","year":"2005","unstructured":"Garcia JM, Garcia-Touza M, Hijazi RA et al (2005) Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90:2920\u20132926. doi: 10.1210\/jc.2004-1788","journal-title":"J Clin Endocrinol Metab"},{"key":"1500_CR30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","volume":"4","author":"MN Pollak","year":"2004","unstructured":"Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505\u2013518","journal-title":"Nat Rev Cancer"},{"key":"1500_CR31","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1002\/ijc.24202","volume":"124","author":"MA Rowlands","year":"2009","unstructured":"Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416\u20132429","journal-title":"Int J Cancer"},{"key":"1500_CR32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2011.04.004","volume":"307","author":"J Han","year":"2011","unstructured":"Han J, Jogie-Brahim S, Harada A, Oh Y (2011) Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-\u03baB signaling. Cancer Lett 307:200\u2013210. doi: 10.1016\/j.canlet.2011.04.004","journal-title":"Cancer Lett"},{"key":"1500_CR33","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2010-08-299784","volume":"118","author":"JH Kim","year":"2011","unstructured":"Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, Lee HY (2011) Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1\/2 activation and Egr-1-mediated transcriptional events. Blood 118:2622\u20132631. doi: 10.1182\/blood-2010-08-299784","journal-title":"Blood"},{"key":"1500_CR34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/BF02303570","volume":"1","author":"RF Wolf","year":"1994","unstructured":"Wolf RF, Ng B, Weksler B, Burt M, Brennan MF (1994) Effect of growth hormone on tumor and host in an animal model. Ann Surg Oncol 1:314\u2013320","journal-title":"Ann Surg Oncol"},{"key":"1500_CR35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0006-291X(02)03028-0","volume":"301","author":"T Hanada","year":"2003","unstructured":"Hanada T, Toshinai K, Kajimura N et al (2003) Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 301:275\u2013279","journal-title":"Biochem Biophys Res Commun"},{"key":"1500_CR36","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/1097-0142(19940301)73:5<1499::AID-CNCR2820730529>3.0.CO;2-O","volume":"73","author":"DL Bartlett","year":"1994","unstructured":"Bartlett DL, Charland S, Torosian MH (1994) Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer 73:1499\u20131504","journal-title":"Cancer"},{"key":"1500_CR37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0039-6060(05)80199-0","volume":"117","author":"DL Bartlett","year":"1995","unstructured":"Bartlett DL, Stein TP, Torosian MH (1995) Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery 117:260\u2013267","journal-title":"Surgery"},{"key":"1500_CR38","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/1055-9965.EPI-11-0179","volume":"20","author":"S Rohrmann","year":"2011","unstructured":"Rohrmann S, Linseisen J, Becker S et al (2011) Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 20:2174\u20132182","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1500_CR39","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/cncr.24917","volume":"116","author":"K Lundholm","year":"2010","unstructured":"Lundholm K, Gunnebo L, Korner U et al (2010) Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 116:2044\u20132052. doi: 10.1002\/cncr.24917","journal-title":"Cancer"},{"issue":"suppl 3","key":"1500_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000053156","volume":"51","author":"E Ghigo","year":"1999","unstructured":"Ghigo E, Arvat E, Broglio F et al (1999) Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Horm Res 51(suppl 3):9\u201315","journal-title":"Horm Res"},{"key":"1500_CR41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1056\/NEJMcibr1106880","volume":"365","author":"KC Fearon","year":"2011","unstructured":"Fearon KC (2011) Cancer cachexia and fat-muscle physiology. N Engl J Med 365:565\u2013567","journal-title":"N Engl J Med"},{"key":"1500_CR42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1164\/rccm.167.2.211","volume":"167","author":"American Thoracic Society\/American College of Chest Physicians","year":"2003","unstructured":"American Thoracic Society\/American College of Chest Physicians (2003) Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167:211\u2013277","journal-title":"Am J Respir Crit Care Med"},{"key":"1500_CR43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.nut.2009.06.015","volume":"26","author":"LH Jakobsen","year":"2010","unstructured":"Jakobsen LH, Rask IK, Kondrup J (2010) Validation of handgrip strength and endurance as a measure of physical function and quality of life in healthy subjects and patients. Nutrition 26:542\u2013550","journal-title":"Nutrition"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1500-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1500-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1500-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T10:53:14Z","timestamp":1594291994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1500-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1500-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,16]]}}}